RBC Capital Sticks to Their Buy Rating for Karyopharm Therapeutics (KPTI)
RBC Capital analyst Brian Abrahams maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research Report) today and set a price target of ...
Today1d
Walmart gets a new logo and people are talking. Here's why
Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...
Gilead Sciences Inc. stock underperforms Friday when compared to competitors
This was the stock's second consecutive day of losses.
Neurocrine (NBIX) Receives a Hold from RBC Capital
RBC Capital analyst Brian Abrahams maintained a Hold rating on Neurocrine (NBIX – Research Report) yesterday and set a price target of $148.00.